Date of Defense
Spring 4-27-2000
Department
Biological Sciences
First Advisor
Tom Dueweke, Pharmacia
Second Advisor
Sandra Newport, Pharmacia
Third Advisor
David Slade, Pharmacia
Abstract
Approximately 2% of the world's adult population (170,000,000) is infected with the hepatitis C virus (HCV). Available treatments, α-interferon alone or the combination a α-interferon and ribavirin, help clear only 50% of HCV infections. The side effects of this therapy include fatigue, fever, weight, appetite loss, and some neurological effects leading to behavioral changes. More effective agents are currently unavailable. The purpose of this project was to engineer three truncation forms of a RdRp derived from HCV positive patient serum. This was achieved by deleting 21, 55, and 63 amino acids from the C terminus. These constructs were verified by DNA sequencing, and their ability to express soluble forms of the predicted polypeptides was confirmed. Follow-up characterization by Pharmacia Corporation has proved these deletion constructs to be useful for heterologous expression of NS5b truncation forms.
Recommended Citation
Predenkiewicz, Amy, "Expression of Soluble Hepatitis C Virus Ns5b Protein in E. Coli" (2000). Honors Theses. 244.
https://scholarworks.wmich.edu/honors_theses/244
Access Setting
Honors Thesis-Campus Only